GenSight Biologics (Euronext: SIGHT), announced that the French Competent Authority, the National Agency for Medicines and Health Products Safety (Agence Nationale de Sécurité du Médicament… Read More »GenSight Biologics has received approval for “LUMEVOQ” for LHON (with ND4 mutations) for a Cohort Temporary Authorization for use in France
An expert clinical research team, based at the University of Bonn, Germany, has reported a short-term real-world outcome study for intravitreal brolucizumab for neovascular AMD. … Read More »A University of Bonn report provides real-world outcome study on brolucizumab for neovascular AMD (nAMD)
Researchers based at the Università degli Studi della Campania “Luigi Vanvitelli”, Naples, Italy, have reported a multicentric longitudinal study with mutations in the CEP290 gene.… Read More »Non-syndromic subjects with mutations in the CEP290 gene have been identified among an Italian cohort of 32 IRD patients
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the July 18th, 2021 edition of EURETINA’s web-based digital magazine,… Read More »July 18th, 2021: “EURETINA-Brief”© Issue No. 239
Genentech (Roche Group [SIX: RO, ROG; OTCQX: RHHBY]), has announced that the U.S. FDA has accepted a Biologics License Application (BLA), under priority review, for… Read More »Genentech (Roche [SIX: RO, ROG; OTCQX: RHHBY]) has submitted a “Port Delivery System” with ranibizumab for the treatment of wet/neovascular age-related macular degeneration (nAMD)
An international consortium of researchers, led in the UK, with Japan, USA, India and Switzerland, have reported results of a systematic review on complications in… Read More »A systematic review using the CONSORT Extension for Harms framework has presented the reporting of complications in retinal detachment surgical trials.
Researchers based at the School of Genetics & Microbiology, Trinity College, Dublin, have reported significant progress on next-generation sequencing (NGS) applications on a range of… Read More »Next-generation sequencing strategies have increased the proportion of resolved diagnoses for several IRDs.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the July 2nd, 2021 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »July 2nd, 2021: “EURETINA-Brief”© Issue No. 238
REGENXBIO Inc. (Nasdaq: RGNX), a clinical-stage biotechnology company has reported that 42 patients have been enrolled in the RGX- 314-001 study (NCT03066258) with up to… Read More »Regenxbio Inc. has reported interim results of >40 patients dosing of Phase II for RGX-314 gene therapy treatment for wet AMD
Researchers led by clinical experts at the National Institute for Health Research, Moorfields Biomedical Research Centre, London, have reported results from a Healthy Technology Assessment… Read More »A formal Health Technology Assessment (HTA) reported key results on intravitreal treatments of ranibizumab, aflibercept and bevacizumab for macular oedema due to CRVO.